| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/19/2008 | US7332499 N-[(1R)-1-(2-fluoro-4-{1-[(trifluoromethyl)sulfonyl]-1,2,3,4-tetrahydroquinolin-8-yl}phenyl)ethyl]-1-[(trifluoroacetyl)amino]cyclopropanecarboxamide; bradykinin B1 antagonists or inverse agonists; analgesic and antiinflammatory agent; acute and chronic pain |
| 02/19/2008 | US7332498 N-(3-amino-propyl)-N-[1-(3-benzyl-4-oxo-3,4-dihydro-pyrido[2,3-d]pyrimidin-2-yl)-2-methyl-propyl]-4-methyl-benzamide; kinesin spindle protein inhibitor; cell division, mitosis phase arrest; antiproliferative and antiinflammation agent, hyperplasias, restenosis, cardiac hypertrophy, autoimmune disorders |
| 02/19/2008 | US7332497 Pyrazolopyrimidines as therapeutic agents |
| 02/19/2008 | US7332496 Methods of using sodium channel blockers |
| 02/19/2008 | US7332495 Aralkyl-ketone piperazine derivatives and their uses as new antalgic or ataractic agent |
| 02/19/2008 | US7332494 Method for treating allergies using substituted pyrazoles |
| 02/19/2008 | US7332493 [3-Methyl-4-(pyridin-3-yloxy)-phenyl]-(6-piperidin-3-ylethynyl-quinazolin-4-yl)-amine; selective inhibitors of receptor tyrosine kinases and non-receptor tyrosine kinases (eg: Ick, src, abl) or serine/threonine kinases (e.g.: cyclin dependent kinases); carcinoma |
| 02/19/2008 | US7332492 Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by NP Y5 receptor |
| 02/19/2008 | US7332491 cyclin-dependent and serine/threonine kinases inhibitor; cell cycle arrest in the G2/M phase; antiproliferative and antitumor agent: leukemia, sarcoma, lung, breast, prostate, pancreas cancer; autoimmune diseases: arthritis, Alzheimer's disease |
| 02/19/2008 | US7332490 inhibit smooth muscle cell proliferation by modulating Heparan Sulfate Proteoglycans (HSPGs); inhibit or block glycated protein and Advanced Glycation Endproducts (AGE) produced induction of the signaling-associated inflammatory response in endothelial cells; antiproliferative and antiinflammatory agent |
| 02/19/2008 | US7332489 Methods and compositions of novel triazine compounds |
| 02/19/2008 | US7332488 Methods and compositions of novel triazine compounds |
| 02/19/2008 | US7332487 Nitrogen-containing 5-membered ring compound |
| 02/19/2008 | US7332486 9-(4-carboxyphenyl)-6-cyclopropylamino-2-trifluoromethylpurine; side effect reduction; cognition activator, antidepressants, neuroleptic agent, schizophrenia, Alzheimer's disease, schizophrenia, Parkinson's, Huntington's, Pick's, Creutzfeld-Jakob, cardiovascular diseases, HIV |
| 02/19/2008 | US7332485 Peptide deformylase inhibitors |
| 02/19/2008 | US7332484 2,4-pyrimidinediamine compounds and their uses |
| 02/19/2008 | US7332483 3-(5-benzamido-2-chlorophenyl)-7-methoxy-3,4-dihydroquinazolin-4-one;cytokines (tumor necrosis factor and interleukins) inhibitor; antiinflammatory agent, rheumatoid arthritis, osteoarthritis, psoriasis, chronic obstructive pulmonary disease |
| 02/19/2008 | US7332482 Using 1-fluoro -25-hydroxy epicholecalciferol |
| 02/19/2008 | US7332481 Thrombopoietin mimetics |
| 02/19/2008 | US7332480 Compositions for the regulation of cytokine activity |
| 02/19/2008 | US7332479 Extracellular NAD+ and cADPR as potent anti-inflammatory agents |
| 02/19/2008 | US7332477 Visible light and ultraviolet (UV) light sensitive composition for DNA transfer comprising an acid sensitive gene transfer agent, a photoacid generator, and a bioactive agent |
| 02/19/2008 | US7332476 Therapy for bacteria infections |
| 02/19/2008 | US7332475 administering a nasal aerosol comprising at least one member selected from reduced and oxidized glutathiones and pharmaceutically acceptable salts thereof and catechin; Coronavirus family or Flavivirus family |
| 02/19/2008 | US7332471 Cross-linked glycopeptide-cephalosporin antibiotics |
| 02/19/2008 | US7332470 Methods and compositions for treating ocular disease |
| 02/19/2008 | US7332335 Increasing expression of p21WAF1/Cip 1 in cells to decrease proliferation of the cells by decreasing levels of PP5 protein in the cells. |
| 02/19/2008 | US7332293 Neutral amino acid transporter binding method |
| 02/19/2008 | US7332276 Administering steroid compound |
| 02/19/2008 | US7332185 Component I selected from alpha acids and beta acids and component II selected from alpha acids, beta acids, essential oils, fats and waxes; specific inhibition of cyclooxygenase-2 with little effect on cyclooxygenase-1 |
| 02/19/2008 | US7332184 Colonic cleansing composition and method |
| 02/19/2008 | US7332183 Multilayer dosage forms containing NSAIDs and triptans |
| 02/19/2008 | US7332180 Transdermal therapeutic system for administering non-steroidal antiphlogistic agents containing carboxyl groups, and a method for the production of the same |
| 02/19/2008 | US7332178 lactose-free infant formula; stability can be achieved without reliance upon complex antioxidation systems, and instead relies upon the use of selectively high ascorbyl palmitate concentrations, alone or in combination with at least about 300 ppm by weight of cystine and/or cysteine |
| 02/19/2008 | US7332177 Administering melatonin to ameliorate or prevent symptoms of hypertension developing in a patient who is resistant to the antihypertensive effect of an antihypertensive compound |
| 02/19/2008 | US7332175 Long-acting drug combinations for the treatment of respiratory complaints |
| 02/19/2008 | US7332149 Diagnosis, therapy of cancer, rheumatoid arthritis, for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature, imaging tumors, atherosclerosis, restenosis, cardiac ischemia, and myocardial reperfusion injury |
| 02/19/2008 | US7332105 Stabilizer mixture comprising specific compounds of the 2,4-bis-(4-phenylphenyl)-6-(2-hydroxyphenyl)-1,3,5-triazine class and selected other UV absorbers as protectants against damage by light, heat and oxygen |
| 02/19/2008 | US7331951 Devices and methodologies useful in body aesthetics |
| 02/19/2008 | CA2481723C 5ht2c receptor modulators |
| 02/19/2008 | CA2468435C Process for the production of an immunosuppressant |
| 02/19/2008 | CA2436572C Perylenequinones for use as photosensitizers and sonosensitizers |
| 02/19/2008 | CA2431565C Pharmaceutical compositions based on anticholinergics and ciclesonide |
| 02/19/2008 | CA2383977C Stably preserving oxygen infusion |
| 02/19/2008 | CA2380924C Compositions for treating viral infections, and methods therefor |
| 02/19/2008 | CA2369726C Powder inhaler for combined medicament |
| 02/19/2008 | CA2348024C Granular, free-flowing pharmaceutical composition, and straw-like dosage form for oral administration thereof |
| 02/19/2008 | CA2338901C Prevention of migraine recurrence |
| 02/19/2008 | CA2333516C Arrangement for the removal of cuttings and gas arising from drilling operations |
| 02/19/2008 | CA2328927C Benzamide derivatives for the treatment of diseases mediated by cytokines |
| 02/19/2008 | CA2326761C Antitumor agent |
| 02/19/2008 | CA2316310C Gamma-glutamyl and beta-aspartyl containing immunomodulator compounds and methods therewith |
| 02/19/2008 | CA2310049C Use of a mixture of a diol and an alpha-hydroxy acid for the treatment of hyperkeratotic skin diseases |
| 02/19/2008 | CA2307824C Processes for producing 7-isoindolinequinolonecarboxylic acid derivatives and intermediates therefor,salts of 7-isoindolinequinolonecarboxylic acids, hydrates thereof, and compositions containing the same as active ingredient. |
| 02/19/2008 | CA2304698C Endothelin antagonist and beta receptor blocking agent as combined preparations |
| 02/19/2008 | CA2301723C Butyrate derivatives in the treatment of fibromyalgia and chronic fatigue syndrome |
| 02/19/2008 | CA2289702C High efficiency encapsulation of charged therapeutic agents in lipid vesicles |
| 02/19/2008 | CA2288321C Preparation of isoflavones from legumes |
| 02/19/2008 | CA2286756C Use of zinc hyaluronate against peptic ulcer |
| 02/19/2008 | CA2277207C Use of dichlorobenzyl alcohol for preparing a preparation for topical treatment of inflammation and a preparation containing dichlorobenzyl alcohol |
| 02/19/2008 | CA2273240C Compositions and methods for treating or preventing inflammatory diseases |
| 02/19/2008 | CA2265893C Oily patches for external use containing diclofenac sodium |
| 02/19/2008 | CA2259584C Plasters containing isosorbide dinitrate |
| 02/19/2008 | CA2253287C A process for producing a recombinant polypeptide involving the addition of an inhibitor of metal-dependent proteases or chymotrypsins to the cell culture medium |
| 02/19/2008 | CA2237023C Improved formulation for administration of steroid compounds |
| 02/19/2008 | CA2226582C Non-allosteric gabaa agonists for treating sleep disorders |
| 02/19/2008 | CA2220505C N,o-carboxymethylchitosan for prevention of surgical adhesions |
| 02/19/2008 | CA2218553C 2,4-dichlorobenzyl alcohol and amylmetacresol against hiv infection |
| 02/19/2008 | CA2209858C Il-2r-associated polypeptide and dna molecules coding therefor |
| 02/19/2008 | CA2207100C Pyrimidine derivatives |
| 02/19/2008 | CA2206366C Substituted 2-naphthoylguanidines, process for their preparation, their use as a medicament or diagnostic, and medicament containing them |
| 02/19/2008 | CA2205175C A polynucleotide tuberculosis vaccine |
| 02/19/2008 | CA2199004C Preparation of multivesicular liposomes for controlled release of active agents |
| 02/19/2008 | CA2197210C Intravenous alendronate formulations |
| 02/19/2008 | CA2173976C Phenylacetate and derivatives alone or in combination with other compounds against neoplastic conditions and other disorders |
| 02/19/2008 | CA2162260C Methods and formulations for use in treating oophorectomized women |
| 02/19/2008 | CA2132613C Method and compositions for enhancing white blood cell functioning on a mucosal or cutaneous surface |
| 02/19/2008 | CA2121364C Vaccines for actinobacillus pleuropneumoniae |
| 02/19/2008 | CA2113726C Use of tetrahydrocarbazone derivatives as 5ht1 receptor agonists |
| 02/14/2008 | WO2008019395A2 Compounds for improving learning and memory |
| 02/14/2008 | WO2008019388A2 Milnacipran for the treatment of fatigue associated with fibromyalgia syndrome |
| 02/14/2008 | WO2008019378A1 Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies |
| 02/14/2008 | WO2008019357A2 Indole compounds |
| 02/14/2008 | WO2008019346A2 Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes |
| 02/14/2008 | WO2008019306A2 Aryl amino acid derivatives as inhibitors of lta4h (leukotriene a4 hydrolase) for treating inflammation |
| 02/14/2008 | WO2008019302A1 Pyrazolylphenyl and pyrrolylphenyl inhibitors of lta4h for treating inflammation |
| 02/14/2008 | WO2008019284A1 Phenoxymethylalkyne inhibitors of lta4h for treating inflammation |
| 02/14/2008 | WO2008019276A2 Solid forms of (3'-chlorobiphenyl-4-yl)(1-(pyrimidin-2-yl)piperidin-4-yl)methanone and methods of their use |
| 02/14/2008 | WO2008019240A2 3, 6-bridged tylosin derivatives |
| 02/14/2008 | WO2008019212A2 Compositions containing chalcones and use thereof |
| 02/14/2008 | WO2008019198A1 Steroid-containing sustained release intraocular implants and related methods |
| 02/14/2008 | WO2008019146A2 Aqueous dronabinol formulations |
| 02/14/2008 | WO2008019139A2 Inhibitors of pyruvate kinase and methods of treating disease |
| 02/14/2008 | WO2008019136A2 Transdermal atomoxetine formulations and associated methods |
| 02/14/2008 | WO2008019135A1 Antiproliferative activity of the leiodermatolide class of macrolides |
| 02/14/2008 | WO2008019124A1 Heteroaryl compounds useful as inhibitors of e1 activating enzymes |
| 02/14/2008 | WO2008019115A2 Formulations for parenteral delivery of compounds and uses thereof |
| 02/14/2008 | WO2008019109A2 Stabilization of lorazepam |
| 02/14/2008 | WO2008019106A1 Methods and compositions for the treatment of pulmonary hypertension using a combination of a calcium channel blocker and a phosphodiesterase inhibitor |
| 02/14/2008 | WO2008019070A2 Pharmaceutical compositions of trospium for treating smooth muscle hyperactivity disorders |